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ABSTRACT:
Introduction: The annual global incidence of Guillain-Barre Syndrome is approximately 1–2 per 100,000 person-years.
Data on Guillain-Barre Syndrome is very rare from Pakistan, we conducted a retrospective study to assess the clinical
presentation, and treatment response of these patients.
METHODOLOGY:
A retrospective observational study was conducted at the Neurology Department, Pakistan Institute of Medical
Sciences. A total of 45 patients medical record was reviewed and noted. Administrative permission from head of the
Department was taken for using the medical record and study was approved by the hospital ethics committee.
Diagnosis was made on the basis of clinical signs and symptoms and the specific laboratory investigations i.e. lumbar
puncture for CSF investigation, electromyography and nerve conduction study. Data analysis was conducted in SPSS
software.
RESULTS:
Mean age was 38.7 years, with majority 40 years. Females were predominant 31 (68.9%). Most of the patients had
AIDP 25 (55.6%) and AMAN 14 (31.1%) variants. There were 25 (55.6%) patients with preceding infections i.e.
gastrointestinal tract and upper respiratory tract infection. Most patients presented in Autumn 18 (40.0%) and
Summer seasons 14 (31.1%). Plasma exchange treatment was done in 37 (82%), whereas 7 (15.8%) were managed
by IV Ig treatment. After treatment fatigue 33(73.2%), and pain 25(55.5%) were frequent symptoms. Majority had
improved functional status after treatment, However, 6 (13.3%) patients were able to walk only with help and 5
(11.1%) were bedridden. None of them died. The mean disability rating index was 50.1 ± 15.4.
Conclusion: In conclusion, overall, outcome of Guillain-Barre Syndrome patient is favorable, although fatigue and pain
remain the common complaints in sequela. It has affected predominantly female population and most patients were
below 40 years of age. Almost one fourth cases had no response to therapy and these patients were bedridden or
unable to walk without help.
KEYWORDS; Clinical features, Guillain-Barre Syndrome, Immunotherapy, Plasma exchange, Therapy outcome.

INTRODUCTION:
Guillain–Barré syndrome (GBS) is less common, but a
fatal, immune- mediated disease of the peripheral
nervous system and the nerve roots.1The primary
etiology is mostly infection triggered.2 The annual global
incidence of GBS is approximately 1–2 per 100,000
person- years. Data suggests that it occurs more
frequently in males and there is a gradual increase in
incidence with age, however, it can affect any age
group.3
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Clinically the patients with GBS usually have weakness
and sensory signs in the legs that progresses to the
arms and cranial nerves, although the clinical
presentation of the disease is heterogeneous and
several distinct clinical variants exist. About 30% GBS
leads to intensive care ventilator dependent due to
respiratory muscle weakness, with subsequent
increase risk of death.4 The major clinical manifestation
is weakness, mainly symmetrical, that evolves with

24

VOL. 15 (4) OCTOBER-DECEMBER 2020

dissociation. The subtypes of GBS was classified on the
basis electromyography and nerve conduction study
(axonal motor, axonal motor and sensory or
demyelinating).

time. The average period from onset to Nadir of illness
is 8 days.5
The overall duration of GBS is < 12 weeks in routine
and most of the patients are expected to have
complete remission in the severity of illness.6
Approximately mortality occurs in 10% of GBS patients,
usually from respiratory failure, cardiac arrhythmia, or
pulmonary embolism, and 20% are left with deficits in
ambulation or respiration one year later.7

Patient included in this study was 13 to 60 years, with
history of less than 4 weeks of progressive, symmetrical
weakness with areflexia or hyporeflexia. Weakness
supported with cranial nerve involvement or sensory
symptoms Patient was recruited during all seasons with
or without history of preceding illness. Patient who were
less than 13 and above 60 years of age excluded.
Patient already diagnosed and taking treatment for
neuropathy secondary to metabolic disease (Diabetes,
Hypothyroidism, Chronic kidney disease, Vitamin B12
deficient, Toxins) were excluded.

In the US, GBS is a significant contributor to new
long-term disability for at least 1,000 persons per year
and many more elsewhere. Between 25,000 to
50,000, persons are experiencing at least some
residual effects from GBS. However, younger patient
has better prognosis with relatively less residual
sequele.8

Table 1: Demographic features of study patients (n=45)

Though the primary immunotherapy with either plasma
exchange (PE) or immunoglobulin (IVIg) is one of the
cornerstone of the treatment.9,10 At current there is no
consensus and no approved treatment for debilitating
fatigue and motor weakness in GBS patients who have
not fully recovered, leading to significantly reduced
functional status and quality of life for many.11,12,13

%age

13 to 20

6

13.3%

21 to 30

16

35.6%

31 to 40

6

13.3%

41 to 50

3

6.6%

51 to 60

8

17.7%

61 or above

6

13.3%

Mean ± SD

Since GBS is rare condition, the evidence on its
complications is not commonly generated. A review by
Ahmed SI revealed some observations on GBS over the
years from Pakistan. The overall incidence ranges
between
1.7/100000/population
to
3.8/100000/population in the country.14 The primary
aim of this study was to assess the symptoms and
Residual weakness and Functional Status of patient
post therapy, secondly to determine seasonal variation
of GBS.

38.7 ± 19.1

Gender
Male

14

31.1%

Female

31

68.9%

The study information included demographic (age,
gender), clinical (variants, preceding infection, type of
infection, autonomic dysfunction, ventilator support
and seasonal presentation), treatment status (type of
treatment, post treatment symptoms, functional status
and residual weakness).

METHODOLOGY:
This retrospective study was carried out at the
Neurology Department, Pakistan Institute of Medical
Sciences, Islamabad in a period of 2 years from 1st July
2018 to 30th June 2020 A total of 45 cases of GBS
presented during this period whose medical record was
available for analysis. Administrative permission from
head of the Department was taken for using the
medical record and study was approved by the hospital
ethics committee.

The primary outcome was to quantify the clinical
presentation of patients with GBS and to see the
outcome after treatment. Secondly, the seasonal
variation of GBS was also measured.
Data was analyzed in SPSS version 20.0. The
categorical variables like clinical presentation,
treatment, type of infection and post treatment
symptoms were measured as frequency and
percentages. The continuous numerical variables like
age and disability rating index (residual weakness) were
measured as mean and standard deviations.

The diagnosis of GBS was made on the basis of clinical
signs and symptoms symmetrical and the specific
laboratory investigations i.e. lumbar puncture for CSF
investigation to demonstrate cytological-albumin
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No. of cases
Age (years)

RESULTS:
There were 45 cases of GBS in this study. The mean
age of patients was 38.7 years, majority of them were
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below 40 years. Females were predominant, n=31
(68.9%). Most of the patients had AIDP, n=25 (55.6%)
and AMAN, n=14 (31.1%) variants. There were 25
(55.6%)
patients
with
preceding
infections;
gastrointestinal tract and upper respiratory tract
infection were the infection types. Three (6.6%)
patients each had autonomic dysfunction and required
ventilator support.
The presentation of GBS was assessed according to
seasonal variation. Most of the patients presented in
(September, October, November) Autumn, n=18
(40.0%) and (June, July, August) Summer seasons,
n=14 (31.1%). In this study most of the patients were
treated using PLEX treatment (5, sessions 200-250 ml
of plasma per Kg weight) n=37 (82%), whereas n=7
(15.8%) were managed by IV Ig treatment (0.4mg/Kg in
divided doses). (Figure I) and (Figure II)
Majority of patient was falling in HUGES Grade 3-5 in
pre-treatment group and at discharge patient
improvement after immunotherapy. We evaluated the
condition of patients after 3 months interval post
therapy. The common symptoms after the treatment
were fatigue, n-=33 (73.2%), pain, n=25 (55.5%),
depression, n=17 (37.7%) and muscle wasting, n=16
(35.5%). The other frequent symptoms were tremors,
dysaesthesia and ataxia. The majority of the patients
had improved functional status after the treatment.
There were 26 (57.7%) patients with minor sign
symptoms (tremor, dysasthesia, and ataxia). Moreover,
8 (17.7%) patients were able to walk 5 meters without
help, whereas 6 (13.3%) patients were able to walk five
meters only with help and 5 (11.1%) of the patients
were bedridden, unable to walk. None of the current
study patients died, albeit 3 (6.6%) required
mechanical ventilation. The mean disability rating index
was 50.1 ± 15.4 and ranging from 30 to 60. (Table 3)
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of GBS is common but results on sequel is limited. This
study was planned keeping in view the local context
where scientific base on GBS is limited specially, the
outcome of therapies such as IVIG and Plasma
exchange.
As witnessed the variants of GBS were AMAN and
AMSAN in majority of the current study patients,
however, AIDP presented as the most frequent. This
fact has been proven by many previous studies as
well.15 AMAN and AMSAN are two frequent variants
characterized by an immune system attack mainly
focused at the axons rather than Schwann cells and
myelin.16, 17 Ho et al, revealed that patients could be
categorized into AIDP (86.3%), AMAN (7.8%), and
AMSAN (5.9%) according to electrophysiological
findings of GBS.18
The findings of the current study are comparable with
many previous studies on the topic from different parts
of the world. A previous local study by Yaqoob et al
reviewed 125 34 cases between 1995 to 2003. The
investigators reported that male gender was more likely
to have GBS, however, it occurred in all age groups.
Before GBS their patients had GI and URTI infections.
Moreover, their patients were managed with IVIG and
Plasma exchange and no significant difference in the
outcome of two treatments was observed.19 In the
present study though we witnessed more females to be
affected by GBS, however, age distribution was similar
to that of Yaqoob et al study. The preceding infections
were also GI and URTI in the current study. Moreover, in
the current study we also noticed similar outcome with
IVIG and plasma exchange.
Another local study by Wali M and colleagues compared
the outcome of Plasmapheresis and Immunoglobulin
treatment in GBS patients and reported that there is no
difference in the therapeutic effect of both treatment
regimens.20 These findings are similar to our results
where we also witnessed that both plasma exchange or
IVIG treatment are similar in treating GBS. Other
investigators have also witnessed that outcome is good
in almost 80-90% patients with Guillain-Barre
syndrome (GBS) in terms of motor recovery and
functional outcome, 21 However, in the long run about
20% patients still face severe motor disability.22 This
was comparable to the current results as well, it was
noticed that around 25% of patients had still poor
functional ability in terms of walk with aid only and
bedridden state despite being treated for a long period.
The patients with severe GBS condition do not fully
recover with IVIg or plasma exchange, There is scientific
base suggesting that in critical conditions of GBS the

DISCUSSION:
The Guillain-Barre syndrome patients in the current
study presented with AIDP and AMAN variants and
majority having preceding infections like upper
respiratory tract infection and gastrointestinal
infections.
After
treatment
with
intravenous
Immunoglobulin and Plasma exchange the majority of
patients recovered and were found with minor signs or
symptoms and were able to run or walk without help.
However, few cases were still bedridden and few others
were not able to move without aid. Fatigue and pain
were the two most frequent symptoms post therapy.
The evidence regarding epidemiology and management
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non-responsive patients could be given a second dose
of IVIg after a gap and recovery is certain.23 However,
our patient only received treatment from either PLEX or
IVIG’s. Though immunotherapy could be used in critical
conditions, they must be opted taking into
consideration the cost factors and the clinical status
(staging, complications, and other comorbid
conditions) of individual patients.24
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